Quick Answer
ENDRA Life Sciences Inc. reported Stockholders Equity of $2.26 million for the year ending 2025.
- ENDRA Life Sciences Inc. showed a decrease of -11.7% in Stockholders Equity from 2024 to 2025.
- This data is from ENDRA Life Sciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$1.38 million | Q2 2017: $7.78 million | Q3 2017: $7.17 million | Q1 2018: $2.83 million | Q2 2018: $1.94 million | Q3 2018: -$457.6 thousand | Q1 2019: $3.80 million | Q2 2019: $1.82 million | Q3 2019: $1.40 million | Q1 2020: $2.52 million | Q2 2020: $976.9 thousand | Q3 2020: $3.33 million | Q1 2021: $17.85 million | Q2 2021: $14.99 million | Q3 2021: $13.16 million | Q1 2022: $9.07 million | Q2 2022: $13.33 million | Q3 2022: $10.20 million | Q1 2023: $4.50 million | Q2 2023: $6.93 million | Q3 2023: $5.20 million | Q1 2024: $3.70 million | Q2 2024: $8.99 million | Q3 2024: $6.60 million | Q1 2025: $1.75 million | Q2 2025: $1.47 million | Q3 2025: $171.4 thousand.
- Over the full 10 years of available data (2016 to 2025), ENDRA Life Sciences Inc.'s Stockholders Equity has grown by 352.9%.
- Historical annual values: Fiscal year 2025: $2.26 million | Fiscal year 2024: $2.56 million | Fiscal year 2023: $5.66 million | Fiscal year 2022: $7.20 million | Fiscal year 2021: $10.78 million | Fiscal year 2020: $7.17 million | Fiscal year 2019: $4.76 million | Fiscal year 2018: $6.25 million | Fiscal year 2017: $5.28 million | Fiscal year 2016: -$893.8 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: